PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Azathioprine - Transplant immunosuppression
PAD Profile : Azathioprine - Transplant immunosuppression
Brand Names Include :
Jayempi
Traffic Light Status
Status 1 of 2.
Status :
Red
Important
Formulations :
- Suspension
- Tablets
Important Information :
For NEW patients - funded by NHS England. GPs should not accept any new request to start prescribing post-transplant
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Status 2 of 2.
Status :
Blue
Important
Formulations :
- Suspension
- Tablets
Important Information :
For EXISTING patients only - GPs may continue prescribing for existing post-transplant patients only. NHS England are looking to repatriate these patients in the future. GPs must not accept requests to prescribe for new patients.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Guidelines
No guidelines returned.
Other Drugs
Other Indications
- Inflammatory bowel disease
- Hepatology Indications
- Haematology Indications
- Dermatology indications
- Rheumatology indications
- Uveitis
- Respiratory disease indications
- Renal indications
- Oral disease indications
- Neurology indications
- Scleritis
- Alopecia
Additional Documents
No additional documents returned.
Committee Recommendations
Date
Committee Name
Narrative
06 March 2024
Not Set
This drug falls under the responsibility of NHS England Specialised Commissioning and should therefore not be prescribed in Primary Care.
Clinicians / specialists within the Acute setting should only prescribe in line with their Trust formulary / pharmacy advice.
GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.
Associated BNF Codes
08. Malignant Disease and Immunosuppression
08.02.01. Antiproliferative immunosuppressants